Christopher J Trabbic1, Sage M George2, Evan M Alexander1, Shengnan Du2, Jennifer M Offenbacher1, Emily J Crissman1, Jean H Overmeyer2, William A Maltese3, Paul W Erhardt4. 1. Center for Drug Design and Development, Department of Medicinal and Biological Chemistry, University of Toledo College of Pharmacy and Pharmaceutical Sciences, 2801 W. Bancroft Ave., Toledo, OH 4360, USA. 2. Department of Biochemistry and Cancer Biology, University of Toledo College of Medicine and Life Sciences, 3000 Arlington Ave., Toledo, OH 43614, USA. 3. Department of Biochemistry and Cancer Biology, University of Toledo College of Medicine and Life Sciences, 3000 Arlington Ave., Toledo, OH 43614, USA. Electronic address: william.maltese@utoledo.edu. 4. Center for Drug Design and Development, Department of Medicinal and Biological Chemistry, University of Toledo College of Pharmacy and Pharmaceutical Sciences, 2801 W. Bancroft Ave., Toledo, OH 4360, USA. Electronic address: paul.erhardt@utoledo.edu.
Abstract
Certain indolyl-pyridinyl-propenone analogues kill glioblastoma cells that have become resistant to conventional therapeutic drugs. Some of these analogues induce a novel form of non-apoptotic cell death called methuosis, while others primarily cause microtubule disruption. Ready access to 5-indole substitution has allowed characterization of this position to be important for both types of mechanisms when a simple methoxy group is present. We now report the syntheses and biological effects of isomeric methoxy substitutions on the indole ring. Additionally, analogues containing a trimethoxyphenyl group in place of the pyridinyl moiety were evaluated for anticancer activity. The results demonstrate that the location of the methoxy group can alter both the potency and the mechanism of cell death. Remarkably, changing the methoxy from the 5-position to the 6-position switched the biological activity from induction of methuosis to disruption of microtubules. The latter may represent a prototype for a new class of mitotic inhibitors with potential therapeutic utility.
Certain indolyl-pyridinyl-propenone analogues kill n class="Disease">glioblastoma cells that have become resistant to conventional therapeutic drugs. Some of these analogues induce a novel form of non-apoptotic cell death called methuosis, while others primarily cause microtubule disruption. Ready access to 5-indole substitution has allowed characterization of this position to be important for both types of mechanisms when a simple methoxy group is present. We now report the syntheses and biological effects of isomeric methoxy substitutions on the indole ring. Additionally, analogues containing a trimethoxyphenyl group in place of the pyridinyl moiety were evaluated for anticancer activity. The results demonstrate that the location of the methoxy group can alter both the potency and the mechanism of cell death. Remarkably, changing the methoxy from the 5-position to the 6-position switched the biological activity from induction of methuosis to disruption of microtubules. The latter may represent a prototype for a new class of mitotic inhibitors with potential therapeutic utility.
Authors: Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher Journal: Clin Cancer Res Date: 2010-04-06 Impact factor: 12.531
Authors: Christopher J Trabbic; Heather M Dietsch; Evan M Alexander; Peter I Nagy; Michael W Robinson; Jean H Overmeyer; William A Maltese; Paul W Erhardt Journal: ACS Med Chem Lett Date: 2014-01-09 Impact factor: 4.345
Authors: Grégory Dupeyre; Guy G Chabot; Sylviane Thoret; Xavier Cachet; Johanne Seguin; Daniel Guénard; François Tillequin; Daniel Scherman; Michel Koch; Sylvie Michel Journal: Bioorg Med Chem Date: 2006-03-10 Impact factor: 3.641
Authors: Shengnan Du; Jeffrey G Sarver; Christopher J Trabbic; Paul W Erhardt; Allen Schroering; William A Maltese Journal: Cancer Chemother Pharmacol Date: 2018-11-13 Impact factor: 3.333
Authors: Xabier Del Corte; Adrián López-Francés; Ilia Villate-Beitia; Myriam Sainz-Ramos; Edorta Martínez de Marigorta; Francisco Palacios; Concepción Alonso; Jesús M de Los Santos; José Luis Pedraz; Javier Vicario Journal: Pharmaceuticals (Basel) Date: 2022-04-22
Authors: Delia Preti; Romeo Romagnoli; Riccardo Rondanin; Barbara Cacciari; Ernest Hamel; Jan Balzarini; Sandra Liekens; Dominique Schols; Francisco Estévez-Sarmiento; José Quintana; Francisco Estévez Journal: J Enzyme Inhib Med Chem Date: 2018-12 Impact factor: 5.051